PL337201A1 - Composition containing 5-[4-[2- ( n-methyl-n-2-pyridyl) amino ethoxy] benzyl] triazinolydino-2,4-dione - Google Patents

Composition containing 5-[4-[2- ( n-methyl-n-2-pyridyl) amino ethoxy] benzyl] triazinolydino-2,4-dione

Info

Publication number
PL337201A1
PL337201A1 PL98337201A PL33720198A PL337201A1 PL 337201 A1 PL337201 A1 PL 337201A1 PL 98337201 A PL98337201 A PL 98337201A PL 33720198 A PL33720198 A PL 33720198A PL 337201 A1 PL337201 A1 PL 337201A1
Authority
PL
Poland
Prior art keywords
triazinolydino
dione
pyridyl
benzyl
methyl
Prior art date
Application number
PL98337201A
Other languages
English (en)
Inventor
Jai Patel
Hamish Ross
Jeffrey Roger Granett
Robin Price
Paul Nigel Wray
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PL337201A1 publication Critical patent/PL337201A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL98337201A 1997-06-05 1998-06-02 Composition containing 5-[4-[2- ( n-methyl-n-2-pyridyl) amino ethoxy] benzyl] triazinolydino-2,4-dione PL337201A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
PL337201A1 true PL337201A1 (en) 2000-08-14

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98337201A PL337201A1 (en) 1997-06-05 1998-06-02 Composition containing 5-[4-[2- ( n-methyl-n-2-pyridyl) amino ethoxy] benzyl] triazinolydino-2,4-dione

Country Status (29)

Country Link
EP (1) EP0998284A1 (ja)
JP (1) JP2001521553A (ja)
KR (1) KR20010013410A (ja)
CN (3) CN1526391A (ja)
AP (1) AP1214A (ja)
AR (2) AR008198A1 (ja)
AU (1) AU8215098A (ja)
BG (1) BG104048A (ja)
BR (1) BR9810405A (ja)
CA (2) CA2333352A1 (ja)
CO (1) CO4940400A1 (ja)
DZ (1) DZ2510A1 (ja)
EA (1) EA002384B1 (ja)
GB (1) GB9711683D0 (ja)
HU (1) HUP0004070A3 (ja)
ID (1) ID24264A (ja)
IL (1) IL133074A0 (ja)
MX (1) MXPA99011322A (ja)
NO (2) NO995938L (ja)
NZ (2) NZ523725A (ja)
OA (1) OA11306A (ja)
PE (1) PE78899A1 (ja)
PL (1) PL337201A1 (ja)
SK (1) SK164899A3 (ja)
TR (2) TR199902963T2 (ja)
TW (1) TW570797B (ja)
UY (1) UY25032A1 (ja)
WO (1) WO1998055122A1 (ja)
ZA (2) ZA984826B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE246191T1 (de) 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
KR100744359B1 (ko) 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
SG47100A1 (en) * 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
KR19990036290A (ko) * 1995-08-10 1999-05-25 로즈 암스트롱 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
AU3552697A (en) * 1996-07-12 1998-02-09 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
NO995938L (no) 2000-02-02
ZA9811572B (en) 1999-07-22
AP9901696A0 (en) 1999-12-31
AU8215098A (en) 1998-12-21
NZ523725A (en) 2004-09-24
TR199902963T2 (xx) 2000-02-21
CN1526391A (zh) 2004-09-08
CA2292629C (en) 2004-01-06
CN1259050A (zh) 2000-07-05
CN1112926C (zh) 2003-07-02
PE78899A1 (es) 1999-10-22
EP0998284A1 (en) 2000-05-10
NO20040738L (no) 2000-02-02
WO1998055122A1 (en) 1998-12-10
AP1214A (en) 2003-10-08
CN1430959A (zh) 2003-07-23
GB9711683D0 (en) 1997-08-06
BR9810405A (pt) 2000-08-29
SK164899A3 (en) 2000-11-07
CO4940400A1 (es) 2000-07-24
ZA984826B (en) 1999-08-03
JP2001521553A (ja) 2001-11-06
OA11306A (en) 2003-10-22
EA002384B1 (ru) 2002-04-25
CA2333352A1 (en) 1998-12-10
TR200002790T2 (tr) 2001-11-21
ID24264A (id) 2000-07-13
EA199901116A1 (ru) 2000-06-26
DZ2510A1 (fr) 2003-01-25
BG104048A (bg) 2000-07-31
NZ513922A (en) 2001-09-28
KR20010013410A (ko) 2001-02-26
MXPA99011322A (es) 2004-12-02
UY25032A1 (es) 1998-11-26
CA2292629A1 (en) 1998-12-10
HUP0004070A2 (hu) 2002-02-28
NO995938D0 (no) 1999-12-03
IL133074A0 (en) 2001-03-19
HUP0004070A3 (en) 2002-03-28
AR008198A1 (es) 1999-12-29
AR015120A1 (es) 2001-04-18
TW570797B (en) 2004-01-11

Similar Documents

Publication Publication Date Title
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
PL300235A1 (en) 5-{2-[4-(1,2-benzoisothiazolyl-3)-1-piperozinyl] ethyl}-6-chloro-1,3-dihydro-2h-indolone-2 hydrochloride monohydrate
AU8441798A (en) Tricyclically substituted oxazolidinones
PL341146A1 (en) Maleic 5-[4-[2-(n-methyl-n-(2-pyridil)amino)ethoxy]benzyl]thiazolydin-2,4-dione salt hydrate as a pharmacological agent
PL337201A1 (en) Composition containing 5-[4-[2- ( n-methyl-n-2-pyridyl) amino ethoxy] benzyl] triazinolydino-2,4-dione
AU7907498A (en) Novel heterocyclic compounds
AUPP003197A0 (en) New heterocyclic compounds
AU2616199A (en) Novel bicyclene-substituted oxazolidinones
AU7907298A (en) Novel heterocyclic compounds
AP2000001830A0 (en) Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
NO2009002I1 (no) 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid
ZA972973B (en) Substituted [2-(1-piperazinyl)ethoxy]methyl compounds.
ZA984795B (en) New thiazolidinedione oxazolidinedione and oxadiazolidinedione derivatives
AU2231397A (en) Thiazolidine-2,4-dione derivatives
AU6291098A (en) Novel heterocyclic compounds
IL125453A0 (en) 4-(Benzo-1,3-dioxylyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists
IL160144A0 (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2, 4-dione
MXPA03001956A (es) La sal de clorhidrato de 5-[4-[2-(n-metil, -n-metil-n -(2-piridil) amino) etoxi] bencil] tiazolidin-2, 4-diona.
HUP9802874A3 (en) Process for making 2-(methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole using methyldithiocarbazinate
AUPO622597A0 (en) New heterocyclic compounds
AU6103399A (en) Substituted pyrrolidinone, thiazolidinone or oxazolidinone as herbicides
HUP0003710A3 (en) 2-{3-[4-(2-t-butyl-6-trifluoromethylpyridin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarate and pharmaceutical composition containing this compound
AU8440498A (en) 5-(3-phenyl-3-oxo-propyl)-1h-tetrazole derivatives
AU5437398A (en) Improved hand-held container for predissolving detergent composition
AUPO527597A0 (en) Novel heterocyclic compounds